Abstract
Dyspnea is a general term used to characterize a range of qualitatively distinct descriptors which may contribute to our understanding of the mechanisms of dyspnea. In general the language of dyspnea complements physiological measurements, essential to a comprehensive understanding of exercise tolerance and dyspnea. Like leg exercise, arm exercise is associated with increased dynamic hyperinflation which correlates with increases in dyspnea, and arm effort in moderately to severely obstructed patients. These patients speak in an interrupted fashion, unable to sustain long sentence because the downstream excursion in end expiratory lung volume is likely to increase the amount of tidal expiratory flow limitation and dyspnea. Patients often spontaneously employ breathing retraining strategies to relieve dyspnea. Pursed-lip breathing, impacts on dyspnea by decreasing end expiratory volumes of the chest wall. Finally, a method is proposed to quantify the presence and degree of Hoovers sign and evaluate the agreement between clinical and quantitative analysis.
Keywords: Dyspnea, speech activities, perception of bronchoconstriction, pursed-lip breathing, Hoover's sign
Current Respiratory Medicine Reviews
Title: Symptoms and Signs
Volume: 4 Issue: 4
Author(s): Giorgio Scano, Loredana Stendardi, Barbara Binazzi and Francesco Gigliotti
Affiliation:
Keywords: Dyspnea, speech activities, perception of bronchoconstriction, pursed-lip breathing, Hoover's sign
Abstract: Dyspnea is a general term used to characterize a range of qualitatively distinct descriptors which may contribute to our understanding of the mechanisms of dyspnea. In general the language of dyspnea complements physiological measurements, essential to a comprehensive understanding of exercise tolerance and dyspnea. Like leg exercise, arm exercise is associated with increased dynamic hyperinflation which correlates with increases in dyspnea, and arm effort in moderately to severely obstructed patients. These patients speak in an interrupted fashion, unable to sustain long sentence because the downstream excursion in end expiratory lung volume is likely to increase the amount of tidal expiratory flow limitation and dyspnea. Patients often spontaneously employ breathing retraining strategies to relieve dyspnea. Pursed-lip breathing, impacts on dyspnea by decreasing end expiratory volumes of the chest wall. Finally, a method is proposed to quantify the presence and degree of Hoovers sign and evaluate the agreement between clinical and quantitative analysis.
Export Options
About this article
Cite this article as:
Scano Giorgio, Stendardi Loredana, Binazzi Barbara and Gigliotti Francesco, Symptoms and Signs, Current Respiratory Medicine Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339808786263806
DOI https://dx.doi.org/10.2174/157339808786263806 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Design, Synthesis, and Delivery Studies of Organotin(IV) based HCV Inhibitor
Infectious Disorders - Drug Targets Chemokines and Receptors as Targets in Anti-Inflammatory Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Current Neuropharmacology Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia
Current Neuropharmacology Endothelin Signalling in the Cardiac Myocyte and its Pathophysiological Relevance
Current Vascular Pharmacology Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Microalbuminuria and the Hypertensive Disorders of Pregnancy
Current Hypertension Reviews The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease
Current Alzheimer Research Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research 18FDG-PET/CT in Traumatic Brain Injury Patients: The Relative Hypermetabolism of Vermis Cerebelli as a Medium and Long Term Predictor of Outcome
Current Radiopharmaceuticals Molecular Strategies for the Treatment of Huntingtons Disease
Current Pharmacogenomics